中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 自动化研究所
  3. 中国科学院自动化研究所
  4. 中国科学院分子影像重点实验室
Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma

文献类型：期刊论文

作者Song, Jiangdian1,2; Tian, Jie3; Zhang, Lina2; Qu, Xiujuan2; Qian, Wei4,5; Zheng, Bin5,6; Zhang, Lina7; Zhao, Jia2; Niu, Meng8; Zhou, Mu9
刊名EUROPEAN RADIOLOGY
出版日期2019-05-01
卷号29期号:5页码:2388-2398
ISSN号0938-7994
关键词Biomarkers Tumor Carcinoma Squamous cell Prognosis
DOI10.1007/s00330-018-5912-2
通讯作者Liu, Yunpeng(ypliu@cmu.edu.cn) ; Zhao, Mingfang(mfzhao@cmu.edu.cn)
英文摘要ObjectivesTo establish a pre-therapy prognostic index model (PIM) of the first-line chemotherapy aiming to achieve accurate prediction of time to progression (TTP) and overall survival among the patients diagnosed with locally advanced (stage III) or distant metastasis (stage IV) lung squamous cell carcinoma (LSCC).MethodsNinety-six LSCC patients treated with first-line chemotherapy were retrospectively enrolled to build the model. Fourteen epidermal growth factor receptor (EGFR)-mutant LSCC patients treated with first-line EGFR-tyrosine kinase inhibitor (TKI) therapy were enrolled for validation dataset. From CT images, 56,000 phenotype features were initially computed. PIM was constructed by integrating a CT phenotype signature selected by the least absolute shrinkage and selection operator and the significant blood-based biomarkers selected by multivariate Cox regression. PIM was then compared with other four prognostic models constructed by the CT phenotype signature, clinical factors, post-therapy tumor response, and Glasgow Prognostic Score.ResultsThe signature includes eight optimal features extracted from co-occurrence, run length, and Gabor features. By using PIM, chemotherapy efficacy of patients categorized in the low-risk, intermediate-risk, and high-risk progression subgroups (median TTP=7.2months, 3.4months, and 1.8months, respectively) was significantly different (p<0.0001, log-rank test). Chemotherapy efficacy of the low-risk progression subgroup was comparable with EGFR-TKI therapy (p=0.835, log-rank test). Prognostic prediction of chemotherapy efficacy by PIM was significantly higher than other models (p<0.05, z test).ConclusionThe study demonstrated that the PIM yielded significantly higher performance to identify individual stage III-IV LSCC patients who can potentially benefit most from first-line chemotherapy, and predict the risk of failure from chemotherapy for individual patients.Key Points center dot TTP and OS of first-line chemotherapy in individual stage III-IV LSCC patients could be predicted by pre-therapy blood-based biomarkers and image-based signatures.center dot Risk status of pre-therapy indicators affected the efficacy of first-line chemotherapy in stage III-IV LSCC patients.center dot Those stage III-IV LSCC patients who were able to achieve similar efficacy to EGFR-TKI therapy through chemotherapy were identified.
WOS关键词OPEN-LABEL ; HEPATOCELLULAR-CARCINOMA ; IMAGING PHENOTYPES ; CANCER ; PREDICTION ; SURVIVAL ; PHASE-3 ; MULTICENTER ; DOCETAXEL ; RISK
资助项目National Key R&D Program of China[2016YFC1303800] ; China Postdoctoral Science Foundation[2018 M630310]
WOS研究方向Radiology, Nuclear Medicine & Medical Imaging
语种英语
出版者SPRINGER
WOS记录号WOS:000463157200025
资助机构National Key R&D Program of China ; China Postdoctoral Science Foundation
源URL[http://ir.ia.ac.cn/handle/173211/24916]  
专题自动化研究所_中国科学院分子影像重点实验室
通讯作者Liu, Yunpeng; Zhao, Mingfang
作者单位1.China Med Univ, Sch Med Informat, Shenyang, Liaoning, Peoples R China
2.China Med Univ, Dept Med Oncol, Hosp 1, Shenyang 110001, Liaoning, Peoples R China
3.Chinese Acad Sci, Inst Automat, CAS Key Lab Mol Imaging, Beijing, Peoples R China
4.Univ Texas El Paso, Coll Engn, El Paso, TX 79968 USA
5.Northeastern Univ, Sino Dutch Biomed Engn Sch, Shenyang, Liaoning, Peoples R China
6.Univ Oklahoma, Med & Biol Informat Engn, Norman, OK 73019 USA
7.China Med Univ, Hosp 1, Dept Radiol, Shenyang, Liaoning, Peoples R China
8.China Med Univ, Hosp 1, Dept Intervent Therapy, Shenyang, Liaoning, Peoples R China
9.Stanford Univ, Dept Radiol, AIMI Ctr, San Francisco, CA USA
推荐引用方式
GB/T 7714		 Song, Jiangdian,Tian, Jie,Zhang, Lina,et al. Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma[J]. EUROPEAN RADIOLOGY,2019,29(5):2388-2398.
APA Song, Jiangdian.,Tian, Jie.,Zhang, Lina.,Qu, Xiujuan.,Qian, Wei.,...&Zhao, Mingfang.(2019).Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma.EUROPEAN RADIOLOGY,29(5),2388-2398.
MLA Song, Jiangdian,et al."Development and validation of a prognostic index for efficacy evaluation and prognosis of first-line chemotherapy in stage III-IV lung squamous cell carcinoma".EUROPEAN RADIOLOGY 29.5(2019):2388-2398.

入库方式： OAI收割

来源：自动化研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。